leisure time -WSS

leisure time

author：hotspot 2025-09-30 17:02:41 - browse：98669

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Mega Millions pot grows to $1.25 billion after no winner

explore

Wikipedia

WSS

What the airline industry can learn from medicine

NEJM study link tiny plastics in blood vessels to heart problems

Novo Nordisk obesity pill bests Wegovy in early trial

UnitedHealth quietly bought dozens of outpatient centers

No plane should take off without an EpiPen onboard

Vertex non

leisure time

leisure time

explore

Walensky prepares to leave CDC — and Congress — behind

Micronoma's microbiome cancer diagnostic approach under fire

Alkermes shareholders re

Novo Nordisk obesity pill bests Wegovy in early trial

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What it’s like to watch children die of measles

Guidelines to prevent youth baseball injuries need more muscle

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Tori Bowie and the unacceptable rates of Black maternal death

5 important ways Henrietta Lacks changed medical science

knowledge

Sage hopes for a blockbuster in antidepressant now before FDA

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

First medicine developed to treat MASH expected to be approved soon

With psoriasis trial ahead, Alumis raises $259 million

Amylyx ALS drug failure raises questions and concerns

In his State of the Union, Biden takes clear aim at 'Big Pharma'

focus

explore

Wikipedia

explore